Source: Business Wire
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–KEYTRUDA Plus Chemotherapy Reduced Risk of Death by 27% Vs Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
Inside Big Pharma’s work with celebs
Source: Business Insider
Summary List Placement Hello, Welcome back to the workweek. I, for one, have never been less excited to receive a flurry of texts from friends than I was Friday night, when we learned that Supreme Court Justice Ruth Bader Ginsburg had died at 87 of complications related to pancreatic cancer . I’ll be spending a lot of this week thinking about her legacy in healthcare and what might come next as the Supreme Court prepares to hear arguments related to the Affordable Care Act. In healthcare news, we’re already off to a busy start with the news that Illumina is acquiring its once-spinout Grail, a company focused on early cancer detection testing. Over the years, Grail has racked up more than $1.9 billion in funding from the likes of Jeff Bezos and Bill Gates and pharma giants like Merck. Prior to Illumina swooping in, Grail had recently filed to go public. The CDC reversed course yet again, removing widely condemned language about not testing asymptomatic people for the coronavirus The CDC is once again recommending that people get tested for the coronavirus if they’ve been in close contact with an infected person — even if they’re not showing symptoms.
Merck’s Keytruda delays recurrence and distant metastasis vs. placebo in skin cancer (NYSE:MRK)
Source: Seeking Alpha
Merck (NYSE:MRK) and the European Organisation for Research and Treatment of Cancer (EORTC) announce new and updated findings from the Phase 3 EORTC1325/KE
AstraZeneca, Merck Lynparza shows positive action in late-stage prostate cancer study (NYSE:AZN)
Source: Seeking Alpha
AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK) announce final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a statist
LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
Source: Business Wire
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM gene mutations, a subpopulation of homologous recombina
LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial
Source: Business Wire
KENILWORTH, N.J.–(BUSINESS WIRE)—- $MRK #MRK–LYNPARZA Reduced Risk of Death by 31% for Men with BRCA1/2 or ATM-Mutated mCRPC Who Progressed Following Enzalutamide or Abiraterone in Ph 3 Trial
Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Source: Business Wire
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)—- $MRK #MRK–Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types
Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Source: Business Wire
KENILWORTH, N.J., & BRUSSELS–(BUSINESS WIRE)—- $MRK #MRK–Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
AstraZeneca’s Lynparza shows positive effect in BRCA-mutated ovarian cancer (NYSE:AZN)
Source: Seeking Alpha
AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK) announce that LYNPARZA demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st
Merck: Uncertainty Reflected In Analyst Estimates (NYSE:MRK)
Source: Seeking Alpha
For established businesses, dividends and earnings per share growth are the primary drivers of total returns on share investments.
